167 related articles for article (PubMed ID: 25558614)
1. [68Ga-DOTA-PET for neuroendocrine tumours].
Loimaala A; Mäenpää H; Lipponen T; Schildt J; Kämäräinen EL; Karhumäki L; Ahonen A
Duodecim; 2014; 130(19):1931-8. PubMed ID: 25558614
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-DOTA-peptides in the diagnosis of NET.
Ambrosini V; Fanti S
PET Clin; 2014 Jan; 9(1):37-42. PubMed ID: 25029932
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
4.
Briganti V; Cuccurullo V; Berti V; Di Stasio GD; Linguanti F; Mungai F; Mansi L
Curr Radiopharm; 2020; 13(3):166-176. PubMed ID: 31886756
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.
Kagna O; Pirmisashvili N; Tshori S; Freedman N; Israel O; Krausz Y
AJR Am J Roentgenol; 2014 Dec; 203(6):1317-23. PubMed ID: 25415711
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
8. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
Briganti V; Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276
[TBL] [Abstract][Full Text] [Related]
9. [68Ga-DOTATOC PET/CT for Diagnosing Neuroendocrine Tumors].
Koyasu S; Shimizu Y; Nakamoto Y
Gan To Kagaku Ryoho; 2022 Aug; 49(8):821-825. PubMed ID: 36046963
[TBL] [Abstract][Full Text] [Related]
10. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours.
Sundin A
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):803-18. PubMed ID: 23582920
[TBL] [Abstract][Full Text] [Related]
11. Imaging of NETs with PET radiopharmaceuticals.
Ambrosini V; Tomassetti P; Franchi R; Fanti S
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):16-23. PubMed ID: 20168283
[TBL] [Abstract][Full Text] [Related]
12. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Bal CS; Gupta SK; Zaknun JJ
Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
14. Gallium-68 PET: a new frontier in receptor cancer imaging.
Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D
Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576
[TBL] [Abstract][Full Text] [Related]
15. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
16. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
[TBL] [Abstract][Full Text] [Related]
18. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Vija L; Dierickx L; Courbon F
Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours.
Lopci E; Nanni C; Rampin L; Rubello D; Fanti S
Minerva Endocrinol; 2008 Sep; 33(3):277-81. PubMed ID: 18846030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]